Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Three Drug Ad Campaigns Face U.S. Lawmaker Scrutiny
Link ID 5505
Title Three Drug Ad Campaigns Face U.S. Lawmaker Scrutiny
Url http://www.medscape.com/viewarticle/574056?src=rss
Description U.S. lawmakers will examine advertising campaigns for the cholesterol drugs Lipitor and Vytorin plus anemia drug Procrit at a hearing on Thursday, a U.S. House of Representatives committee said. Reuters Health Information
Category Articles > Business of Medicine
Keywords
Date May 9, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. The Inhospitable Hospital: No Peace, No Quiet
  Hospitals just keep getting noisier. Can anything be done to find peace and quiet in the hospital? Medscape Nurses
Category:   Articles > Business of Medicine


2. U.S. Medicare Proposes Cuts to Hospice Wages
  The U.S. Medicare insurance program for the elderly on Monday proposed cutting reimbursement for hospice facility wages, which would hurt big chains Odyssey Healthcare and Chemed Corp. Reuters Health Information
Category:   Articles > Business of Medicine


3. Baxter Recalls All Remaining Heparin Vial Products
  Baxter International is now recalling from the market all remaining lots and doses of its heparin sodium multidose and single-dose vials for injection and its heparin lock flush solutions. Medscape Medical News
Category:   Articles > Business of Medicine


4. U.S. Approves UnitedHealth Buying Sierra Health
  Insurer UnitedHealth Group Inc won U.S. antitrust approval on Monday to buy Sierra Health Services Inc, despite criticism of the deal. Reuters Health Information
Category:   Articles > Business of Medicine


5. Tarenflurbil Fails to Meet Primary End Point in Phase 3; End of the Road for Development
  In a brief statement, Myriad Genetics reports that tarenflurbil failed to have a significant effect in mild AD patients in a phase 3 trial and announced that it will not continue development of the compound. Medscape Medical News
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS